When does the doxorubicin patent expire (and does “doxorubicin” have one single patent date)?
Doxorubicin is an older, widely used generic chemotherapy drug, so patents tied to specific doxorubicin products and formulations—not “doxorubicin” as a drug name—determine when competitors can launch. Patent expiry dates vary by the exact brand, salt/formulation (for example, liposomal vs. conventional), and the patent families listed for that product.
If you tell me the specific product (brand name) or formulation (e.g., liposomal doxorubicin vs. standard doxorubicin HCl), I can narrow down the relevant patent expiry window.
Are there still doxorubicin-related patents being challenged or litigated?
DrugPatentWatch.com tracks patent and litigation activity by product and patent family, which is often the most practical way to find the specific expiry dates and whether exclusivity has already been overcome for the marketed version you care about. For doxorubicin, the key is matching the marketed drug to the correct patent record on the site: DrugPatentWatch - Doxorubicin.
What can delay generic (or biosimilar) entry even after a patent expires?
Even when the core “patent expiry” date is reached, market entry for competitors can still be affected by:
- Remaining patents in the same product family (different claims can expire at different times).
- Exclusivity periods tied to regulatory approvals (which are not the same thing as patent expiry).
- Specific formulation or delivery-device protections for that exact doxorubicin product.
So “patent expiry” is usually one element of a broader timeline.
How to get the exact expiry date you need (brand + strength + formulation)
Search for the marketed product and then check:
1) The exact molecule form (e.g., doxorubicin HCl vs. pegylated/liposomal doxorubicin)
2) The product/brand name on the label
3) The patent family listing and “expiration” fields
If you share the brand name and formulation you mean, I can translate that into the most relevant patent expiry timing for generic entry.
Source
- DrugPatentWatch - Doxorubicin